Connect, a cornerstone of San Diego’s life science and technology ecosystem, has appointed James Zanewicz as its new CEO. This appointment marks a pivotal moment for the organization, signaling a strategic shift as it seeks to amplify its impact on the region’s burgeoning innovation landscape.
Zanewicz’s diverse background, spanning biotech business development, academic medicine, and investment, suggests Connect is aiming for a more integrated approach to fostering innovation. His experience at Tulane University, where he rebranded academic medicine and navigated complex hospital partnerships, is particularly relevant as the lines between academic research, commercialization, and healthcare delivery continue to blur. The question now is how this multifaceted experience will translate into a concrete strategic vision for Connect.
This leadership transition arrives at a critical juncture for the San Diego life science cluster. While the region boasts world-class research institutions and a vibrant startup scene, competition from other global biotech hubs is intensifying. Attracting and retaining top talent, securing funding, and navigating regulatory complexities are ongoing challenges that organizations face. Connect’s success in addressing these issues will be crucial not only for its member companies but also for the broader San Diego economy. Zanewicz’s prior involvement with organizations like AUTM and the Biojudiciary Project hints at a focus on strengthening the bridge between academia and industry—a key factor in translating scientific breakthroughs into commercially viable therapies.
Furthermore, Zanewicz’s experience with AI in healthcare, through his podcast, board memberships, and investment fund involvement, aligns with the increasing convergence of life sciences and digital technologies. This raises the question of whether Connect, under his leadership, will prioritize initiatives that support the development and adoption of AI-driven solutions in healthcare and drug discovery. This could involve fostering collaborations between life science and tech companies, attracting investment in AI-focused startups, and providing educational resources on the ethical and regulatory implications of these technologies.
Ultimately, Zanewicz’s success will depend on his ability to leverage Connect’s existing strengths while adapting to the evolving dynamics of the life science industry. His emphasis on “inclusion, data, capital access, and real San Diego stories” suggests a focus on building a more diverse and interconnected ecosystem. The challenge lies in translating these broad goals into tangible outcomes that benefit the entire San Diego innovation community and position it for sustained growth on the global stage.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
